New York, New York--(Newsfile Corp. - September 27, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Annovis Bio, Inc. (NYSE: ANVS) alleging that the Company violated federal securities laws.
Class Period: May 21, 2021 and July 28, 2021
Lead Plaintiff Deadline: October 18, 2021
No obligation or cost to you.
Learn more about your recoverable losses in ANVS:
Annovis Bio, Inc. NEWS - ANVS NEWS
CLASS ACTION CASE DETAILS: The filed complaint alleges that Annovis Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Annovis Bio you have until October 18, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you purchased Annovis Bio securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97719